BHE’s team grew considerably over the past few months. Here’s a look at three of our new team members:
Robert I. Griffiths, MS, ScD: Chief Scientific Officer
Dr. Griffiths has over 25 years of experience in outcomes research, including evaluating the comparative effectiveness and cost-effectiveness of medical technologies and practice in clinical trials, and in electronic health record and insurance claims databases. He has contributed to more than 70 peer-reviewed articles published in medical journals that include the New England Journal of Medicine, JAMA, Cancer, and Blood. Prior to joining BHE, he was a Senior Research Fellow in the Nuffield Department of Primary Care Health Sciences at Oxford University, United Kingdom. Dr. Griffiths received a master’s degree in Science and Technology Studies from Virginia Polytechnic Institute and State University, and a Doctor of Science in Health Policy and Management (concentration health finance) from the Johns Hopkins University Bloomberg School of Public Health. He is currently completing a Doctor of Philosophy (DPhil) in Evidence-Based Health Care at Oxford University, where he is also a member of Balliol College. In addition, Dr. Griffiths holds a part-time faculty appointment at the Johns Hopkins University School of Medicine, Baltimore, MD.
Rahul Jain, PhD: Senior Manager
Dr. Jain’s primary research experience is applied health economics using advanced econometric techniques and he has specialized in pharmacoeconomics, health outcomes research and health policy research. Dr. Jain’s research has also focused on using novel data analytic techniques that address non-random treatment assignment reflecting “real world” treatments patterns within large administrative claims and other databases. Prior to joining Boston Health Economics, Dr. Jain was Research Manager at HealthCore, Inc. and an Assistant Professor at the University of Georgia College of Pharmacy. Dr. Jain has a master’s degree from the Indian Statistical Institute and a PhD in Economics from the State University of New York at Buffalo. He completed his Post-Doctoral fellowship from Department of Pharmaceutical Health Services Research at the University of Maryland Baltimore School of Pharmacy.
Know anyone who would be a good fit for the BHE team?
Written by Jack Fuller, Business Development Manager
Boston Health Economics (BHE), a 19-year-old healthcare analytics firm, is excited to celebrate greater industry use of our leading Instant Health Data (IHD) platform. Over the past few years, IHD has been transforming the way researchers and analysts interact with real-world data for improved insights.
IHD supports rapid analysis of multiple types of data including claims, claims and laboratory results, electronic medical records, hospital, and integrated data sources. Drawing on a respected team of outcomes researchers, physicians, methodologists, and software engineers, IHD has become a standard analytical tool for life science companies looking to leverage real world evidence (RWE) data assets. Through extensive adoption and use of IHD, we have learned countless lessons from our clients and partners, with the main focal points being:
- People matter. Analytics platforms provide speed of analyses and rapid hypothesis testing capabilities, but there is no tool that can replace the analytic decisions made by clinical and statistical experts.
- Benefits of Big Data have been realized for RWE groups. The time is right to leverage advances in computer hardware and software to make optimal use of the wide variety of data assets.
- Speed is everything. The move to value based reimbursement has put even more pressure on companies to provide robust analyses to support products like never before. Stakeholders need answers quickly that can impact company bottom lines.
For the past two decades, BHE has worked with large observational datasets to perform retrospective database studies for clients throughout the life science industry. BHE has constantly been on the cutting edge of utilizing technology to improve the efficiency of our work and has built several tools over the years to improve how we analyze real world evidence. The vision behind IHD was to develop a web-based interface that would remove the technical barriers in transforming data into information that can be shared with key stakeholders. IHD has been leveraged by companies across the life sciences industry, including many of the top 10 pharmaceutical and medical device companies.
Agile analytics will be the key for companies moving forward, which we will explore in greater detail in future articles to come. If you are interested in learning more about IHD and how it can help your organization complete studies in days instead of weeks or months, please reach out to Jack Fuller at firstname.lastname@example.org.
The above is an example of the type of visualization you can build in IHD. This bar chart represents percent of patients who have a Diabetes related hospitalization, stratified by age groupings.